Skip Navigation Links
   
Skip Navigation Links
   

Adjuvant Breast Cancer

Adjuvant Breast Cancer Trials in St. Louis, MO

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer  Alliance A011401 (NCT02750826)  (MBMC Contact:  Diana Christian 314-996-5888)

A phase III randomized placebo controled clinical trial of donepezil in chemotherapy exposed breast cancer survivors with cognitive impairment  WF97116 (NCT02822573) (MBMC Contact:  Diana Christian 314-996-5888)

A phase II double blind dose finding trial of bupropion versus placebo for sexual desire in women with breast or gynecologic cancer  NRG-CC004   (NCT03180294) (MBMC Contact:  Diana Christian 314-996-5888)

PALLAS: PALbociclib CoLlaborative Adjuvant Study:  A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (stage IIA arm closed effective 8/28/17) (NCT02513394) (MBMC Contact: Chris Sanders 314-996-5802)  (AVAILABLE AT MBMC ONLY)

A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer:  The ABC trial  Alliance A011502 (NCT02927249)  (MBMC Contact:  Diana Christian 314-996-5888) 

Randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with >/= 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy  SWOG S1418  (NCT02954874)  (MBMC Contact:  Chris Sanders 314-996-5802)  Check for tissue kit availability before consenting

Randomized phase III trial of adjuvant therapy comparing doxorubicin plus cyclophospahmide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node negative triple negative breast cancer   NRG-BR003 (NCT02488967)   (MBMC Contact: Chris Sanders 314-996-5802)

Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive, and HER2/neu Negative Breast Cancer Post Chemotherapy  (Everolimus/Placebo Provided)
SWOG S1207 (NCT01674140) 
(MBMC Contact: Chris Sanders 314-996-5802 

Randomized phase III post-operative trial of platinum-based chemotherapy vs capecitabine in patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy  ECOG-ACRIN EA1131 (NCT02445391)  (MBMC Contact: Chris Sanders 314-996-5802)

Randomized, double-blind, parallel group, placebo controlled multicenter phase III study to assess the efficacy and safety of otaparib versus placebo as adj tx in pts with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy  NSABP B-55 (NCT02032823) (MBMC Contact: Chris Sanders 314-996-5802)

Randomized, double-blind, placebo-controlled study of testosterone in the adjuvant treatment of postmeneopausal women with aromatase inhibitor-induced arthralgias   Alliance 221102  (NCT01573442) (MBMC Contact:  Diana Christian 314-996-5888)

 
 

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy